| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Contineum Therapeutics, Inc. | CMO & Sr VP, Clinical Dev. | Class A Common Stock | 12,800 | $218,240 | $17.05 | 13 Aug 2024 | Direct |
| Contineum Therapeutics, Inc. | CMO & Sr VP, Clinical Dev. | Stock Option (right to buy) | 110,000 | 31 Jan 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| CTNM | Contineum Therapeutics, Inc. | 31 Jan 2025 | 1 | $0 | 4 | CMO & Sr VP, Clinical Dev. | 31 Jan 2025, 16:38 |
| CTNM | Contineum Therapeutics, Inc. | 13 Aug 2024 | 2 | +$12,928 | 4 | CMO & Sr VP, Clinical Dev. | 14 Aug 2024, 18:03 |
| CTNM | Contineum Therapeutics, Inc. | 24 May 2024 | 1 | $0 | 4 | CMO & Sr VP, Clinical Dev. | 29 May 2024, 17:56 |
| CTNM | Contineum Therapeutics, Inc. | 04 Apr 2024 | 0 | $0 | 3 | CMO & Sr VP, Clinical Dev. | 04 Apr 2024, 17:54 |